Sourcing comparison · Generic Drugs
Tariff & fee savings only, assuming equal product cost — your actual landed cost also depends on price and freight, which vary by supplier.
| Annual import value | Estimated duty & fee savings / year |
|---|---|
| $50,000 | $1,319 |
| $250,000 | $6,594 |
| $1,000,000 | $26,375 |
Savings scale linearly with volume. Enter your exact figure to model it precisely.
Calculate your exact volume →If your generic drugs currently ships from China, the duty bill is worth a second look. China carries roughly 12.5% in duties and fees against 10% for Canada, a spread worth near $2,638 on $100,000 of annual volume. The importers who win this cycle are the ones treating country of origin as a number to optimise, not a given. Read on for the full stack comparison, the policy reasons behind the gap, and a scaling table for your own volume.
The duty layers tell the whole story of the gap. China-made goods carry a 12.5% forced-labor Section 301 duty on its generic drugs, an effective 12.5% once the $49.74 in processing fees are added. Shipped out of Canada, the product is hit with a 10% forced-labor Section 301 duty on its generic drugs, an effective 10% once the $49.74 in processing fees are added. The Merchandise Processing Fee and Harbor Maintenance Fee are charged on customs value, not origin, so they sit at $49.74 on either stack and never contribute to the gap. The arithmetic difference between the stacks is $263.75 per $10,000 entry, all of it in the duty layers since the processing fees are origin-blind. That same per-dollar gap is about $659 on a $25,000 order and $2,638 on $100,000 of annual volume. A buyer placing $25,000 orders sees about $659 of avoidable duty on each one.
Classified in HTS chapter 3004, generic drugs spans products like Generic antibiotics, Blood pressure medications, Diabetes drugs, Cancer generics, Pain relievers, and Vitamins and supplements. Demand for generic drugs is broad and price-sensitive, which is exactly why a duty wedge of this size reshapes who can supply the US market competitively. Finished pharmaceutical products carried a Section 122 carve-out before the surcharge lapsed to 0% sitewide on July 24, 2026. Most finished drugs are duty-free (0% MFN) and not subject to Section 301. Generic drugs are outside the Section 232 pharmaceutical action (Proclamation 11020) because of PATENT STATUS, not because of their HTS classification — chapter 3004 lines are enumerated in the proclamation's Annex I. A generic pharmaceutical article is one not subject to a valid, unexpired US patent and off exclusivity; biosimilar products are excluded on the same basis. A patented drug of the same HTS heading would be in scope at up to 100 percent, so classification alone does not determine the outcome. From Asia-Pacific, China's top US-bound categories include consumer electronics, computers servers, and clothing garments. Absent a trade deal, China's generic drugs is assessed standard duties and whatever surcharges apply. A North America supplier, Canada concentrates its US exports in crude oil petroleum, passenger vehicles, and lumber wood products. Under USMCA, Canada-origin generic drugs that meets the rules of origin can clear duty-free entirely (USMCA 0%, except Section 338 annex goods) — a decisive edge where qualification holds. Different regions — Asia-Pacific versus North America — mean shipping economics deserve a look beside the tariff math. Canada clears this category at a structurally lower rate than China, an edge that persists across order cycles rather than a spot-price blip. Because surcharges have stacked rates well above their statutory base, country of origin has become a first-order cost driver for generic drugs rather than a footnote.
For $100,000 a year of generic drugs, the move from China to Canada is worth about $2,638, scaling to $1,319 at $50,000, $6,594 at $250,000, and $26,375 at $1,000,000. The comparison is generated by running the same inputs through the tariff engine for each origin, which keeps everything but the duty layers equal. These figures reflect tariff and fee savings only, assuming equal product cost — your actual landed cost also depends on price and freight, which vary by supplier. Treat the annual saving as the ceiling on switching cost: as long as moving to Canada costs less than that, the change is accretive. Request parallel quotes from your China incumbent and a vetted Canada source, then compare landed cost with the duty gap held constant. The saving is current today; given the pace of 2026 revisions, verify it again at contract signing. Run your own volume — and a post-Section-122 view — through the interactive Tariff Savings Finder.
At $100,000 of annual import value, switching from China to Canada saves an estimated $2,638 in duties and fees, because the effective tariff rate falls from 12.5% to 10%. The saving scales linearly with volume. These figures reflect tariff and fee savings only, assuming equal product cost — your actual landed cost also depends on price and freight, which vary by supplier.
Canada-origin generic drugs is assessed a 10% forced-labor Section 301 duty, for an effective 10% duty rate before the Merchandise Processing Fee ($36.55) and Harbor Maintenance Fee ($13.19).
China carries an effective 12.5% rate versus 10% for Canada. The gap comes from differences in the base, Section 232 and bilateral rates that apply to each origin.
Tariff rates from Tax Foundation, USITC, and Penn Wharton Budget Model; retaliatory and industry data from the ITA Foreign Retaliations Database and U.S. Census Bureau (NAICS). Last verified .
